Turn Therapeutics Inc. (NASDAQ: TTRX) announced interim analysis results from its Phase 2 trial evaluating GX-03 in adults with moderate-to-severe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE